Guardant Health Q4 rev $155.1M (+22% YoY); GAAP net loss $187.0M incl $83.4M legal accrual; 2024 guidance $655-670M

Guardant Health, Inc.

2023-FY EPS reported -$4.28 revenue$563,948,000

Fourth quarter 2023 revenue $155.1M, up 22% YoY; full year revenue $563.9M, up 25%.
GAAP net loss Q4 $187.0M ($1.58 per share) vs $139.9M ($1.36) prior year, including $83.4M non-recurring legal accrual.
Clinical test volume 46,400 in Q4 (+29% YoY); full year 172,900 (+39% YoY).
2024 revenue guidance $655-670M (16-19% growth); non-GAAP op expense $740-750M; free cash flow -$320 to -$330M.
Cash and marketable securities $1.2B at year-end; Shield PMA submission under FDA review, expect FDA approval and launch in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Guardant Health, Inc. updated its full year 2024 guidance (initiated).

Period: full year 2024
Guidance: initiated
Result: guidance update

Exact text from the filing

Expects full year 2024 revenue to be in the range of $655 to $670 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Guardant Health, Inc. reported the fourth quarter of 2023 results: revenue $155.1 million, net income Net loss was $187.0 million, EPS Net loss per share was $1.58.

Period: the fourth quarter of 2023
Revenue: $155.1 million
Net income: Net loss was $187.0 million
EPS: Net loss per share was $1.58
Result: reported results

Exact text from the filing

leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Revenue of $155.1 million for the fourth quarter of 2023, an increase of 22% over the fourth quarter of 2022 • Reported 46,400 tests to clinical customers and 9,500 tests to biopharmaceutical customers in

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Guardant Health, Inc. reported the full year ended December 31, 2023 results: revenue $563.9 million. Guidance reaffirmed.

Period: the full year ended December 31, 2023
Revenue: $563.9 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Revenue was $563.9 million for 2023, a 25% increase from $449.5 million for the corresponding prior year period

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001576280-24-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.